Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2001

View Archived Issues

Parke-Davis (Pfizer) isothiazolone inhibits early phase of HIV replication

Pharming reports results for Q1 2001

New dietary supplement improves hair growth

New option for patients with refractory B-CLL will be available soon in U.S.

Plans to codevelop ACAT inhibitor for atherosclerosis announced by Lilly, bioMerieux-Pierre Fabre

Pharmacia's Zyvoxam approved in Canada for Gram-positive bacterial infections

Soltara moves into formal review at the FDA

Promising preclinical data reported for argatroban in rat ischemic stroke model

Schering-Plough seeks approval in Japan for Rebetol/Intron combination for hepatitis C

Efficacy and safety of new glutamate receptor antagonist evaluated during a migraine attack

AstraZeneca completes patient enrollment in NSCLC phase III trials of Iressa

ImmunoGen's lead product enters third phase I/II trial

AAN news: proteasome inhibitor PS-519 reduces functional impairment following ICH

Oral heparin completes phase I testing

Dexanabinol exerts long-term neuroprotective effects in stroke, as reported at AAN meeting

Infigen and Immerge BioTherapeutics collaborate on xenotransplantation research

Biopure's Hemopure blood substitute proves highly effective in pivotal trial

Gentamicin tested in patients with muscular dystrophy and stop codon mutations

Vertex licenses Deltagen technology for drug discovery based on gene function

PhotoCure reports update on company progress during the first quarter

Patented series from BMS particularly useful for type 2 diabetes

Etoposide and paclitaxel conjugates prepared by Nobex for improving drug delivery

New vitamin D3 derivatives and their use described by Chugai

Cysteine protease inhibitors undergo research at Kissei

Wakunaga presents novel antibacterial agents devoid of phototoxicity

Preparation, binding and use of novel NMDA antagonists disclosed by Roche

New treatments for gallstones in development at Aventis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...